User login
Key clinical point: Use of hydroxychloroquine (HCQ) is not associated with increased risk of developing heart failure (HF) in patients with rheumatoid arthritis (RA).
Major finding: HCQ cumulative dose was not associated with HF (odds ratio [OR], 0.96 [95% confidence interval (CI), 0.90-1.03] per 100 g). No statistically significant association was found for patients with a cumulative dose of 300 g or more (OR, 0.92; 95% CI, 0.41-2.08). Duration of HCQ use prior to index was not associated with HF (OR, 0.98; 95% CI, 0.91-1.05).
Study details: The data come from a nested case-control study of 143 RA cases diagnosed with HF and 143 non-HF RA controls.
Disclosures: The study was funded by grants from the National Institutes of Health. The authors declared no conflicts of interest.
Source: Sorour AA et al. J Rheumatol. 2021 Jan 15. doi: 10.3899/jrheum.201180
Key clinical point: Use of hydroxychloroquine (HCQ) is not associated with increased risk of developing heart failure (HF) in patients with rheumatoid arthritis (RA).
Major finding: HCQ cumulative dose was not associated with HF (odds ratio [OR], 0.96 [95% confidence interval (CI), 0.90-1.03] per 100 g). No statistically significant association was found for patients with a cumulative dose of 300 g or more (OR, 0.92; 95% CI, 0.41-2.08). Duration of HCQ use prior to index was not associated with HF (OR, 0.98; 95% CI, 0.91-1.05).
Study details: The data come from a nested case-control study of 143 RA cases diagnosed with HF and 143 non-HF RA controls.
Disclosures: The study was funded by grants from the National Institutes of Health. The authors declared no conflicts of interest.
Source: Sorour AA et al. J Rheumatol. 2021 Jan 15. doi: 10.3899/jrheum.201180
Key clinical point: Use of hydroxychloroquine (HCQ) is not associated with increased risk of developing heart failure (HF) in patients with rheumatoid arthritis (RA).
Major finding: HCQ cumulative dose was not associated with HF (odds ratio [OR], 0.96 [95% confidence interval (CI), 0.90-1.03] per 100 g). No statistically significant association was found for patients with a cumulative dose of 300 g or more (OR, 0.92; 95% CI, 0.41-2.08). Duration of HCQ use prior to index was not associated with HF (OR, 0.98; 95% CI, 0.91-1.05).
Study details: The data come from a nested case-control study of 143 RA cases diagnosed with HF and 143 non-HF RA controls.
Disclosures: The study was funded by grants from the National Institutes of Health. The authors declared no conflicts of interest.
Source: Sorour AA et al. J Rheumatol. 2021 Jan 15. doi: 10.3899/jrheum.201180